Your AI-Trained Oncology Knowledge Connection!

Perioperative Immunotherapy the Future of HCC Treatment?

January 22, 2019

By Ahmed Kaseb, MD

Video

Cancer Network spoke with Dr. Ahmed Kaseb about a phase II pilot trial of perioperative immunotherapy for resectable HCC and how the results could change future perioperative treatment of the disease.

Cancer Network spoke with Dr. Ahmed Kaseb about a phase II pilot trial of perioperative immunotherapy for resectable HCC and how the results could change future perioperative treatment of the disease.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos

Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.

Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.

Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences

All rights reserved.